Calzetta, Luigino
Matera, Maria Gabriella
Facciolo, Francesco
Cazzola, Mario
Rogliani, Paola http://orcid.org/0000-0001-7801-5040
Funding for this research was provided by:
Chiesi Farmaceutici has provided unconditional support and funding in this research (NA)
Article History
Received: 20 February 2018
Accepted: 2 April 2018
First Online: 12 April 2018
Ethics approval and consent to participate
: Ethical approval (RS 233.16, 2016; Independent Ethical Committee, Fondazione PTV Policlinico Tor Vergata) and informed consent were consistent with the 2009 National Committee of Bioethics, National Committee of Bio-safety, Biotechnology and Sciences (Italy) recommendations on the collection of biological samples for research purposes, the 2010 Italian ethical and legal recommendations concerning the biobank and the research biorepository (Istituto Nazionale dei Tumori – Independent Ethics Committee, 2010), and the Comitato Nazionale per la Biosicurezza, le Biotecnologie e le Scienze per la Vita (Raccolta di campioni biologici a fini di ricerca, consenso informato, 2009; available at:ExternalRef removed).
: Not applicable.
: LC has participated as advisor in scientific meetings under the sponsorship of Boehringer Ingelheim and Novartis, received non-financial support by AstraZeneca, received a research grant partially funded by Chiesi Farmaceutici, Boehringer Ingelheim, Novartis, and Almirall, and is or has been a consultant to ABC Farmaceutici, Edmond Pharma, Zambon, Verona Pharma, and Ockham Biotech. His department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici.MGM has participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline and Novartis, and has been a consultant to Chiesi Farmaceutici.FF has no conflict of interest to declare.MC has participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Lallemand, Mundipharma, Novartis, Pfizer, Verona Pharma, and Zambon, and has been a consultant to ABC Farmaceutici, Edmond Pharma, Chiesi Farmaceutici, Lallemand, Novartis, Verona Pharma, and Zambon. His department was funded by Almirall, Boehringer Ingelheim, Novartis, and Zambon.PR participated as a lecturer and advisor in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Biofutura, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Group, Mundipharma, and Novartis. Her department was funded by Almirall, Boehringer Ingelheim, Novartis, Zambon and Chiesi Farmaceutici.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.